Werkgroep Cardiologische centra Nederland English

PARADIGM-2314 (Klaar)

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Middel
LCZ 696 vs enalapril
Populatie
hartfalen
Fase
III
Jaar aanvang
2009
Meer informatie
ClinicalTrials.gov

Publicaties: PARADIGM-2314

  • Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.J Am Coll Cardiol - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Hf
  • A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.Eur Heart J - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Hf
  • A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.Eur Heart J - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Hf
  • Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.Circulation - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Hf
  • Discussant: PARADIGM Heart FailureESC 2014 - PARADIGM-2314 - Hf
  • Results of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)ESC 2014 - PARADIGM-2314 - Hf

Publicaties per WCN-studie

Publicaties WCN-studies per WCN-lid